New HIV Prevention Drug Shows 100% Efficacy in Clinical Trial
A new HIV prevention drug, lenacapavir, has shown 100% efficacy in a trial in South Africa and Uganda for young women. It outperformed daily pills like Truvada and Descovy, offering hope for improved prevention methods.
Read original article
A new HIV prevention drug, lenacapavir, has shown 100% efficacy in a clinical trial conducted in South Africa and Uganda. The drug, administered as a twice-yearly injection, provided total protection against HIV infection for young women aged 16 to 25. Compared to daily pills like Truvada and Descovy, lenacapavir demonstrated superior effectiveness in preventing HIV transmission. The trial's success has led to the recommendation to halt the blinded phase and offer participants a choice of PrEP. This breakthrough offers hope for a highly effective prevention tool in the fight against HIV, especially in regions like eastern and southern Africa where young women are disproportionately affected by new infections. The next steps involve transitioning the trial to an open-label phase, submitting results to regulators, and potentially incorporating the drug into WHO guidelines. Ensuring affordability and accessibility will be crucial for widespread adoption of this promising HIV prevention method.
Related
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
New Covid Shots Recommended for Americans 6 Months and Older This Fall
The CDC urges all Americans 6 months and older to get new Covid-19 vaccines this fall. Data shows unvaccinated individuals faced severe outcomes. Vaccination is crucial to curb virus spread and protect vulnerable populations.
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
A new way to prevent HIV delivers dramatic results in trial
A trial of lenacapavir for HIV prevention showed 100% effectiveness, prompting a shift from daily pills to injections. Experts praise its potential for populations with adherence challenges, while efforts focus on accessibility and cost considerations.
HIV breakthrough: Trial shows drug provides 100% protection
A trial in South Africa and Uganda revealed lenacapavir, a new PrEP drug given twice yearly, provided 100% protection against HIV in young women, outperforming daily options. The promising results may offer a more manageable prevention approach.
1 commentsRelease a month ago: https://www.gilead.com/news-and-press/press-room/press-relea...
And lots of discussion: https://news.ycombinator.com/item?id=40742163
Related
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
New Covid Shots Recommended for Americans 6 Months and Older This Fall
The CDC urges all Americans 6 months and older to get new Covid-19 vaccines this fall. Data shows unvaccinated individuals faced severe outcomes. Vaccination is crucial to curb virus spread and protect vulnerable populations.
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
A new way to prevent HIV delivers dramatic results in trial
A trial of lenacapavir for HIV prevention showed 100% effectiveness, prompting a shift from daily pills to injections. Experts praise its potential for populations with adherence challenges, while efforts focus on accessibility and cost considerations.
HIV breakthrough: Trial shows drug provides 100% protection
A trial in South Africa and Uganda revealed lenacapavir, a new PrEP drug given twice yearly, provided 100% protection against HIV in young women, outperforming daily options. The promising results may offer a more manageable prevention approach.